Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 10/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.34 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318469 | 0.87 | MEN1 (0.48) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL3313734 | 0.85 | CHRNB2 (0.42) | MEN1ALDH1A1KMT2ACHRNB2CHRNA3 | |
| SCHEMBL12801568 | 0.82 | DPP4 (0.58) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL25798260 | 0.82 | DPP4 (0.58) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL12801567 | 0.82 | DPP4 (0.58) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL3311606 | 0.82 | DPP4 (0.58) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL2249766 | 0.80 | DPP4 (0.45) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL20385048 | 0.80 | DPP4 (0.45) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL2249769 | 0.80 | DPP4 (0.45) | MEN1ALDH1A1KMT2ADPP4DPP7 | |
| SCHEMBL3397414 | 0.80 | DPP4 (0.45) | MEN1ALDH1A1KMT2ADPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | MEN1 3480/4885ALDH1A1 649/4885KMT2A 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.